Raising Health Supercharging Discovery with Evan Feinberg
16 snips
Oct 31, 2023 Evan Feinberg, founder and CEO at Genesis Therapeutics, talks about using AI in drug discovery and the collaboration between ML, biotech, and chemistry. They discuss how physics-based models can improve drug design, integrating human intuition and predictive AI models, and the importance of a multidisciplinary team in drug discovery programs.
AI Snips
Chapters
Transcript
Episode notes
High School Biotech
- Evan Feinberg interned at a biotech company in high school.
- He witnessed the company's first FDA approval and the impact it had on patients.
Science and Helping Others
- Feinberg's passion lies in using his skills in physics and computer science to help others.
- Computational chemistry holds immense potential for drug discovery.
Limitations of Early ML
- Early machine learning in drug design had limitations.
- Models struggled with extrapolation and finding new chemical matter, unlike other ML domains.